Germany Authorizes GMP Production of Actinium-225
The certification allows for medical-grade radioisotope manufacturing to support ongoing human clinical trials.
Updated on Oct. 28, 2026 in Nuclear
Live Poll
Do you believe the development of new radioisotope therapies is beneficial for healthcare in your country?
German regulators have authorized Eckert & Ziegler Therapeutics to produce the medical radioisotope actinium-225 under Good Manufacturing Practice (GMP) standards. This certification allows the company to manufacture the isotope for use in investigational human clinical trials.
Why it matters
Actinium-225 is a critical component for targeted alpha therapy in oncology, and formal GMP certification is a necessary regulatory step for bringing potential cancer treatments from research into clinical testing phases.
The production process utilizes cyclotron-based irradiation of radium-226 target material. This method, split between the Nuclear Physics Institute and the Braunschweig facility, is designed to reduce actinium-227 and thorium-229 impurities while allowing the recovery and reuse of radium-226.
The players
Eckert & Ziegler Therapeutics
A subsidiary of a global isotope provider specializing in the manufacture and supply of radioactive sources for medical and industrial applications.
Nuclear Physics Institute of the Czech Academy of Sciences
A research institution focused on nuclear physics and neutron science that houses the cyclotron infrastructure used for isotope irradiation.
The details
The manufacturing process relies on cyclotrons—particle accelerators that use electromagnetic fields to propel charged particles—to irradiate radium-226 targets. Following irradiation, the material undergoes chemical processing in Braunschweig to isolate medical-grade actinium-225. By chemically recovering the unconverted radium-226, the facility can recycle the target material for subsequent production cycles, a standard required for scalable radioisotope manufacturing.
Timeline
October 28, 2026: German authorities granted GMP manufacturing authorization.
Early 2027: Commercial-scale operations are scheduled to begin in Jintan, China.
The Tech Race
As pharmaceutical interest in targeted alpha therapies grows, firms are racing to secure stable supplies of medical-grade actinium-225. This GMP milestone marks a shift from experimental bench-scale production to a model capable of supporting standardized clinical pipelines.
This development ensures that researchers and pharmaceutical partners have a certified supply of actinium-225 for human clinical trials. Patients enrolled in future investigational trials will rely on these GMP-certified sources for consistent isotopic purity in their cancer therapies.
The takeaway
This authorization standardizes the production cycle for a high-demand isotope, providing a critical supply chain link for developers of cancer therapeutics. Observers should track the 2027 launch of the Jintan facility to see if the company successfully scales its recycling-based production model to commercial volumes.
What happens next
Operations are scheduled to begin at the joint venture facility in Jintan, China, in early 2027.
Further reading
Learn more about the latest developments in Nuclear medicine and isotope supply chains.
Source note: This article includes information reported by AuntMinnie.
Live Poll
Do you believe the development of new radioisotope therapies is beneficial for healthcare in your country?
